Our Approach
Our Product Candidates
Levering the breadth and depth of our team’s expertise in RNA therapeutics and cancer drug development, we have a promising pipeline with programs against “undruggable” targets STAT 3 and MALAT1. We have a clinical-stage pipeline with our lead program, Danvatirsen, advancing into Phase 2 development, and FTX-001 advancing towards the clinic.
Our Pipeline
Flamingo’s focus is on the development of RNA-targeted therapies for difficult to treat cancers.
Publications
Danvatirsen
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR.
Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P.
Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.
J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.
MALAT-1 & LncRNA
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss.
Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL.
Genes Dev. 2016 Jan 1;30(1):34-51. doi: 10.1101/gad.270959.115. Epub 2015 Dec 23.
PMID: 26701265 Free PMC article.
The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.
Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S.
Cancer Res. 2013 Feb 1;73(3):1180-9. doi: 10.1158/0008-5472.CAN-12-2850.
MALAT1 Long Non-Coding RNA: Functional Implications.
Arun G, Aggarwal D, Spector DL.
Noncoding RNA. 2020 Jun 3;6(2):22. doi: 10.3390/ncrna6020022.
Abstract 1541: LncRNA MALAT1 as a potential therapeutic target in triple negative breast cancer.
Oluwatoyosi Adewunmi, Jeffrey Rosen.
Cancer Res 15 June 2022; 82 (12_Supplement): 1541. https://doi.org/10.1158/1538-7445.AM2022-1541